Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. Coli Publisher Pubmed



Hashemzaei M1 ; Ghoshoon MB1 ; Jamshidi M1 ; Moradbeygi F1 ; Hashemzehi A2
Authors

Source: Recent Patents on Biotechnology Published:2024


Abstract

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder determined by immune-mediated platelet demolition and reduction of platelet production. Romiplostim is a new thrombopoiesis motivating peptibody that binds and stimulates the human throm-bopoietin receptor the patent of which was registered in 2008. It is used to treat thrombocy-topenia in patients with chronic immune thrombocytopenic purpura. Romiplostim is a 60 kDa peptibody designed to inhibit cross-reacting immune responses. It consists of four high-affinity TPO-receptor binding domains for the Mpl receptor and one human IgG1 Fc domain. Escherichia coli is a good host for the fabrication of recombinant proteins such as romiplostim. The expression of a gene intended in E. coli is dependent on many factors such as a protein’s inherent ability to fold, mRNA’s secondary structure, its solubility, its toxicity preferential codon use, and its need for post-translational modification (PTM). This review focuses on the structure, function, mechanism of action, and expressive approach to romiplostim in E. coli. © 2024 Bentham Science Publishers.
Related Docs
View other Related Docs
1. Fcγ1 Fragment of Igg1 As a Powerful Affinity Tag in Recombinant Fc-Fusion Proteins: Immunological, Biochemical and Therapeutic Properties, Critical Reviews in Biotechnology (2017)
2. Multi-Omics Insights Into Autoimmune Thrombocytopenic Purpura, Comprehensive Hematology and Stem Cell Research: Volume 1-5 (2024)
3. Finding Appropriate Signal Peptides for Secretory Production of Recombinant Glucarpidase: An in Silico Method, Recent Patents on Biotechnology (2021)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (1)
Ziba Veisi Malekshahi (1)
Other Related Docs
4. Toll-Like Receptor 7 Regulates Cardiovascular Diseases, International Immunopharmacology (2022)
5. Optimization of Expression and Extraction of Toxocara Canis Recombinant C-Type Lectin Protein in Escherichia Coli Bl21 (De3), Journal of Veterinary Research (2021)
6. Fcrn Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Therapeutic Advances and Clinical Outcomes, Cytokine (2025)
7. When the Victim Becomes the Villain: Platelets As Drivers of Immune Dysregulation in Itp, Journal of Translational Autoimmunity (2025)
8. Il-22 Produced by T Helper Cell 22 As a New Player in the Pathogenesis of Immune Thrombocytopenia, Endocrine# Metabolic and Immune Disorders - Drug Targets (2015)
9. Strategies for the Discovery and Design of Tissue Plasminogen Activators: Insights Into Bioengineering Objectives, Drug Development Research (2025)
10. Efficacy and Safety of Syk and Btk Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence, Mediators of Inflammation (2025)
11. Suitable Signal Peptides for Secretory Production of Recombinant Granulocyte Colony Stimulating Factor in Escherichia Coli, Recent Patents on Biotechnology (2020)
12. Solubilization of Human Interferon Β-1B Inclusion Body Proteins by Organic Solvents, Advanced Pharmaceutical Bulletin (2020)
13. Recent Developments In Recombinant Proteins for Diagnosis of Human Fascioliasis, Acta Parasitologica (2021)
14. Identification of Candidate Biomarkers for Idiopathic Thrombocytopenic Purpura by Bioinformatics Analysis of Microarray Data, Iranian Journal of Pharmaceutical Research (2020)